On May 18, the U.S. the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) to treat urothelial carcinoma. Read more
Get your free subscription to NurseLine!
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.